Axovant Sciences has appointed Medivation founder David Hung, M.D., as CEO. The news sparked a 30% surge in Axovant’s share price as investors cheered the potential implications of the man who led Medivation to a $14 billion buyout taking charge of the Alzheimer’s hopeful.
Hung bowed out as CEO of Medivation after 13 years by engineering one final deal in September: A $14 billion takeover by Pfizer. That deal left Hung $354 million better off, before taxes, and catapulted him toward the top of the list of the most eligible unattached biotech execs. Axovant, an Alzheimer’s player, has pulled off a coup by securing Hung’s services, along with another member of the Medivation management team.
Investors responded to the coup by driving the share price of Axovant up 30%, a considerable feat for a company with a market cap now touching $2 billion.
The surge is, in part, a reflection of the credibility Hung and fellow new arrival Marion McCourt—the former COO of Medivation—bring to the Axovant. The company usually gets a double dose of skepticism because of its chosen therapeutic field and its jaw dropping rise from nowhere to a $315 million IPO.
With Axovant having set its course toward clinical data under the leadership of founder Vivek Ramaswamy, it is questionable how much Hung can influence whether the company succeeds. But the fact that a man with his pick of roles chose Axovant paints it and its prospects in a good light.
The snag in that rosy interpretation of Hung’s arrival is that his reputation is built on success in cancer, not Alzheimer’s. Hung’s track record in Alzheimer’s is blemished.
Medivation began life by picking up Dimebon from Russian researchers and went on to strike a $725 million pact with Pfizer. That unraveled when clinical trial data came up short.
Now, Hung gets another crack at the toughest of indications.
By Nick Paul Taylor
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
